Back to discover
Disease

Tinea

Late-stage therapeutic developmentEmerging research
MeSHTinea
1
Publications
20
Clinical trials
12
Associated genes
2023
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 5 clinical trials with recent milestones.
Major developments
Major clinical milestoneImportant
Comparing the Efficacy of Oral Fluconazole Versus Oral Itraconazole in Treating Resistant Tinea Corporis
Primary completion2026-02-20
Major clinical milestoneImportant
Clinical Study to Assess Tolnaftate 1% With a Novel Vehicle for the Treatment of Tinea Pedis
Primary completion2026-02-28
Clinical Milestones5View
Recently completed 5
Activity timeline5

Clinical trials

17 sponsors · 2 new · 0 completed in the last 12 months (net +2)

The current development programme across all trial phases.

Clinical programme
20
All trials
6
Active
10
Late-stage
6
Completed
Late-stage studies

Comparing the Efficacy of Oral Fluconazole Versus Oral Itraconazole in Treating Resistant Tinea Corporis

Phase 4 · Recruiting · Urooj Fatima

Efficacy and Safety of Topical Amphotericin B Solution in Treatment of Resistant Tinea Capitis

Phase 2/3 · Active, not recruiting · Sohag University

A Randomized,Double-blind,Vehicle-controlled, Parallel-design,Multiple-site Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% (Douglas Pharmaceuticals America Ltd) to Ketoconazole Cream 2% (Teva Pharmaceuticals USA Inc.) in the Treatment of Tinea Pedis.

Phase 3 · Completed · Douglas Pharmaceuticals America Ltd

Phase 3 Study, Randomized, Double-blind, Parallel to Evaluate Ketoconazole and Betamethasone Dipropionate(Candicort®) Compared to Clotrimazole and Dexamethasone Acetate(Baycuten N®) in Relief of Fungal Infections/Dermatophytosis Symptoms.

Phase 3 · Completed · Ache Laboratorios Farmaceuticos S.A.

Phase 3, Multicenter, Double-blind, Randomized, Non-inferiority Clinical Trial of Dapaconazole Cream 2% (Biolab Sanus Farmacêutica Ltda.) Versus Ketoconazole Cream 2% (Nizoral®, Janssen-Cilag Farmacêutica Ltda.) in Patients With Tinea Pedis

Phase 3 · Completed · Biolab Sanus Farmaceutica

A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% (Encube Ethicals Pvt Ltd) to Ketoconazole Cream 2% (G&W Laboratories Inc.) in the Treatment of Tinea Pedis

Phase 3 · Completed · Encube Ethicals Pvt. Ltd.
Recruiting

Comparing the Efficacy of Oral Fluconazole Versus Oral Itraconazole in Treating Resistant Tinea Corporis

Phase 4 · Recruiting · Urooj Fatima

Clinical Study to Assess Tolnaftate 1% With a Novel Vehicle for the Treatment of Tinea Pedis

Phase 2 · Recruiting · Propedix, Inc.

A Single Arm No-treatment Self-controlled Trial Pilot Study Evaluating the Clinical Efficacy and Safety Profile of 20% Cassia Alata Cream Against Tinea Versicolor

Phase 1 · Recruiting · The University of The West Indies

Evaluating the Therapeutic Efficacy of Intra-lesional Immunotherapy Against Recalcitrant Tinea Cruris & Corporis: a Pilot Study

N/A · Recruiting · Abeer Mohamed Abdelaziz Elkholy

Comparative Clinicomycologic and Dermoscopic Study Between Daily and Pulse Therapy of Oral Itraconazole in Tinea Capitis in Children

N/A · Recruiting · Alexandria University
Recently completed

A Randomized,Double-blind,Vehicle-controlled, Parallel-design,Multiple-site Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% (Douglas Pharmaceuticals America Ltd) to Ketoconazole Cream 2% (Teva Pharmaceuticals USA Inc.) in the Treatment of Tinea Pedis.

Phase 3 · Completed · Douglas Pharmaceuticals America Ltd

Phase 3 Study, Randomized, Double-blind, Parallel to Evaluate Ketoconazole and Betamethasone Dipropionate(Candicort®) Compared to Clotrimazole and Dexamethasone Acetate(Baycuten N®) in Relief of Fungal Infections/Dermatophytosis Symptoms.

Phase 3 · Completed · Ache Laboratorios Farmaceuticos S.A.

Phase 3, Multicenter, Double-blind, Randomized, Non-inferiority Clinical Trial of Dapaconazole Cream 2% (Biolab Sanus Farmacêutica Ltda.) Versus Ketoconazole Cream 2% (Nizoral®, Janssen-Cilag Farmacêutica Ltda.) in Patients With Tinea Pedis

Phase 3 · Completed · Biolab Sanus Farmaceutica

A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% (Encube Ethicals Pvt Ltd) to Ketoconazole Cream 2% (G&W Laboratories Inc.) in the Treatment of Tinea Pedis

Phase 3 · Completed · Encube Ethicals Pvt. Ltd.

Clinical Study to Evaluate the Therapeutic Equivalence and Safety of Econazole Nitrate Cream, 1% (Renaissance Pharma, Inc.) to Econazole Nitrate Cream, 1% (Perrigo New York Inc.) in Tinea Pedis

Phase 3 · Completed · Mylan Inc.

A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Product 33525 in Pediatric Subjects With Tinea Corporis

Phase 4 · Completed · Bausch Health Americas, Inc.

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

Dermatophyte infection: from fungal pathogenicity to host immune responses.

Frontiers in immunology · 2023 · 33 cites
Recent publications

Dermatophyte infection: from fungal pathogenicity to host immune responses.

Frontiers in immunology · 2023 · 33 cites
Major themes3
  • Arthrodermataceae1
  • Dermatomycoses1
  • Tinea1
Leading journals1
  • Frontiers in immunology1
Leading researchers3
  • Deng R1
  • Li R1
  • Wang X1
Affiliations (unnormalised)4
  • Beijing Key Laboratory of Molecular Diagnosis on Dermatoses1
  • National Clinical Research Center for Skin and Immune Diseases1
  • Peking University First Hospital1
  • Research Center for Medical Mycology1

Associated genes

12 matches

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

FLG0.66PRSS530.46LY6D0.44CARD90.37RERE0.37TMPRSS50.36FDX10.35DSG10.34MICALL20.34C1orf940.34ADAM300.34AQP20.33

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Fungal infection of keratinized tissues such as hair, skin and nails. The main causative fungi include MICROSPORUM; TRICHOPHYTON; and EPIDERMOPHYTON.

Identifiers
MeSHTinea
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.